Overview

Low dose computed tomography (LDCT) is an effective tool for reducing lung cancer (LC) mortality by enabling early detection. In 2022, the European Commission endorsed LDCT screening for smokers; however, to date, only a few countries have implemented LC screening programmes. Effectively reaching groups most likely to benefit from LC screening and integrating screening with primary prevention methods, such as smoking cessation, remain implementation challenges. Looking ahead, countries must establish mechanisms to monitor programme performance and ensure quality assurance. This article examines the current understanding of these key issues to guide the effective implementation of LC screening programmes in Europe.